A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO)

A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO)

Abstract Background Intrahepatic cholangiocarcinoma (CCA) is amongst the most common primary liver tumors worldwide. CCA carries a bad prognosis prompting research to establish new treatment modalities other than surgery and the current chemotherapeutic regimens adopted. Hence, this trial explores a...

Full description

Bibliographic Details
Main Authors: Charbel Elias, Youssef H. Zeidan, Youssef Bouferraa, Deborah Mukherji, Sally Temraz, Maya Charafeddine, Monita Al Darazi, Ali Shamseddine
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Cancer
Subjects:
Nivolumab
Immunotherapy
PD-1 inhibitor
Cholangiocarcinoma
Biliary tract cancer
Radiotherapy
Online Access:https://doi.org/10.1186/s12885-022-10373-1

Internet

https://doi.org/10.1186/s12885-022-10373-1

Similar Items